Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Webb

Showing results (91-100 of 96) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 96 results.
Diabetes, Obesity & Metabolism|March 12, 2020
A randomized, open-label, active comparator trial assessing the effects of 26 weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetesDavid R Webb, Zin Zin Htike, Daniel J Swarbrick, et al.
Diabetes, Obesity & Metabolism|April 20, 2022
The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double-blind, placebo-controlled trialJack A Sargeant, James A King, Thomas Yates, et al.
Diabetes, Obesity & Metabolism|July 9, 2024
Greater hepatic lipid saturation is associated with impaired glycaemic regulation in men with metabolic dysfunction-associated steatotic liver disease but is not altered by 6 weeks of exercise trainingScott A Willis, Sundus Malaikah, Stephen J Bawden, et al.
Ebiomedicine|February 28, 2025
A humanised ACE2, TMPRSS2, and FCGRT mouse model reveals the protective efficacy of anti-receptor binding domain antibodies elicited by SARS-CoV-2 hybrid immunityFernanda Ana-Sosa-Batiz, Shailendra Kumar Verma, Norazizah Shafee, et al.
Ebiomedicine|October 1, 2024
Influence of Th1 versus Th2 immune bias on viral, pathological, and immunological dynamics in SARS-CoV-2 variant-infected human ACE2 knock-in miceShailendra Kumar Verma, Fernanda Ana-Sosa-Batiz, Julia Timis, et al.
Cell|June 21, 2011
An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzymeDerek F Ceccarelli, Xiaojing Tang, Benoit Pelletier, et al.
Pageof 10

Showing results (91-100 of 96) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 96 results.
Diabetes, Obesity & Metabolism|March 12, 2020
A randomized, open-label, active comparator trial assessing the effects of 26 weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetesDavid R Webb, Zin Zin Htike, Daniel J Swarbrick, et al.
Diabetes, Obesity & Metabolism|April 20, 2022
The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double-blind, placebo-controlled trialJack A Sargeant, James A King, Thomas Yates, et al.
Diabetes, Obesity & Metabolism|July 9, 2024
Greater hepatic lipid saturation is associated with impaired glycaemic regulation in men with metabolic dysfunction-associated steatotic liver disease but is not altered by 6 weeks of exercise trainingScott A Willis, Sundus Malaikah, Stephen J Bawden, et al.
Ebiomedicine|February 28, 2025
A humanised ACE2, TMPRSS2, and FCGRT mouse model reveals the protective efficacy of anti-receptor binding domain antibodies elicited by SARS-CoV-2 hybrid immunityFernanda Ana-Sosa-Batiz, Shailendra Kumar Verma, Norazizah Shafee, et al.
Ebiomedicine|October 1, 2024
Influence of Th1 versus Th2 immune bias on viral, pathological, and immunological dynamics in SARS-CoV-2 variant-infected human ACE2 knock-in miceShailendra Kumar Verma, Fernanda Ana-Sosa-Batiz, Julia Timis, et al.
Cell|June 21, 2011
An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzymeDerek F Ceccarelli, Xiaojing Tang, Benoit Pelletier, et al.
Pageof 10